Follow

BioStock: Scandion Oncology strengthens executive leadership

01 October 2020 - 08:53

As its clinical development program intensifies, Scandion Oncology can start planning for its next phase of the company development and clinical trials of its top candidate, SCO-101, in metastatic colorectal cancer. This means the company is ready to transition into its next phase of development, and it took a major step in that direction by appointing Bo Rode Hansen to the position of CEO. BioStock reached out to the new CEO to learn more about what’s in store for Scandion Oncology in the months to come.

Read the full interview with Bo Rode Hansen, CEO of Scandion Oncology, at biostock.se:

https://www.biostock.se/en/scandion-oncology-strengthens-executive-leadership/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Provided by: Cision
Nasdaq First North GM (Sweden)
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More